Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 5
1981 3
1982 8
1983 3
1984 10
1985 17
1986 18
1987 14
1988 11
1989 18
1990 13
1991 3
1992 15
1993 19
1994 9
1995 17
1996 15
1997 31
1998 28
1999 22
2000 47
2001 65
2002 82
2003 116
2004 125
2005 155
2006 180
2007 189
2008 175
2009 241
2010 231
2011 254
2012 333
2013 309
2014 323
2015 304
2016 255
2017 277
2018 242
2019 290
2020 308
2021 313
2022 259
2023 246
2024 239
2025 39

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,260 results

Results by year

Filters applied: . Clear all
Page 1
Decitabine/Cedazuridine: First Approval.
Dhillon S. Dhillon S. Drugs. 2020 Sep;80(13):1373-1378. doi: 10.1007/s40265-020-01389-7. Drugs. 2020. PMID: 32860582 Free PMC article. Review.
Cedazuridine is a proprietary, patented cytidine deaminase inhibitor that, when added to decitabine, increases oral bioavailability of the drug. In July 2020, decitabine/cedazuridine received its first approval in the USA and Canada for the treatment of MDS and CMML …
Cedazuridine is a proprietary, patented cytidine deaminase inhibitor that, when added to decitabine, increases oral bioavailability o …
Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models.
Li X, Li Y, Dong L, Chang Y, Zhang X, Wang C, Chen M, Bo X, Chen H, Han W, Nie J. Li X, et al. J Clin Invest. 2023 Apr 3;133(7):e165673. doi: 10.1172/JCI165673. J Clin Invest. 2023. PMID: 36853831 Free PMC article.
Treatment with decitabine plus anti-PD-1 promoted the activation and expansion of tumor-infiltrated CD8+ progenitor Tex and efficiently suppressed tumor growth in multiple tumor models. ...Strikingly, decitabine plus anti-PD-1 sustained the expression and activity o …
Treatment with decitabine plus anti-PD-1 promoted the activation and expansion of tumor-infiltrated CD8+ progenitor Tex and efficient …
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR. Garcia-Manero G, et al. Blood. 2020 Aug 6;136(6):674-683. doi: 10.1182/blood.2019004143. Blood. 2020. PMID: 32285126 Free PMC article. Clinical Trial.
This phase 2 study was designed to compare systemic decitabine exposure, demethylation activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs standard decitabine 20 mg/m2 IV. ...Primary end points: mean decitabine syste …
This phase 2 study was designed to compare systemic decitabine exposure, demethylation activity, and safety in the first 2 cycles wit …
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. Lancet Haematol. 2024. PMID: 38135371 Clinical Trial.
Thereafter, all participants received oral decitabine-cedazuridine from the third cycle on until treatment discontinuation. The primary endpoint was total decitabine exposure over 5 days with oral decitabine-cedazuridine versus intravenous decitabine f …
Thereafter, all participants received oral decitabine-cedazuridine from the third cycle on until treatment discontinuation. The prima …
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Kim K, et al. Cancer. 2021 Oct 15;127(20):3772-3781. doi: 10.1002/cncr.33689. Epub 2021 Jul 13. Cancer. 2021. PMID: 34255353 Free PMC article.
The authors investigated the outcomes of patients with TP53(mut) AML who were treated with a 10-day decitabine and venetoclax (DEC10-VEN) (ClinicalTrials.gov identifier NCT03404193). METHODS: Patients with newly diagnosed AML received decitabine 20 mg/m(2) for 10 da …
The authors investigated the outcomes of patients with TP53(mut) AML who were treated with a 10-day decitabine and venetoclax (DEC10- …
Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T, Yamamoto K, Sato N, Enomoto Y, Tanaka Y, Fukuyama T, Satoh H, Kato K, Saitoh K, Ishikawa T, Soga T, Nannya Y, Fukagawa T, Nakanishi M, Kitagawa D, Kitamura T, Goyama S. Yabushita T, et al. Cell Rep. 2023 Sep 26;42(9):113098. doi: 10.1016/j.celrep.2023.113098. Epub 2023 Sep 14. Cell Rep. 2023. PMID: 37714156 Free article.
Decitabine (DAC) is clinically used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ...
Decitabine (DAC) is clinically used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ...
Decitabine and Cedazuridine.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2020 Oct 30;77(22):1809-1811. doi: 10.1093/ajhp/zxaa276. Am J Health Syst Pharm. 2020. PMID: 32945859 No abstract available.
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O, Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Vilque JP, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Amadori S, Venditti A, Huls G; EORTC Leukemia Group, GIMEMA, and German MDS Study Group. Lübbert M, et al. Lancet Haematol. 2023 Nov;10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9. Lancet Haematol. 2023. PMID: 37914482 Free article. Clinical Trial.
Patients were randomly assigned (1:1) to receive decitabine or standard chemotherapy (known as 3 + 7). For the decitabine group, decitabine (20 mg/m(2)) was administered for the first 10 days in the first 28-day cycle, followed by 28-day cycles consisting of …
Patients were randomly assigned (1:1) to receive decitabine or standard chemotherapy (known as 3 + 7). For the decitabine grou …
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen NM, Pfaff KL, Cieri N, Oliveira G, Kim-Schulze S, Ranasinghe S, Leonard R, Robertson T, Morgan EA, Chen HX, Song MH, Thurin M, Li S, Rodig SJ, Cibulskis C, Gabriel S, Bachireddy P, Ritz J, Streicher H, Neuberg DS, Hodi FS, Davids MS, Gnjatic S, Livak KJ, Altreuter J, Michor F, Soiffer RJ, Garcia JS, Wu CJ. Penter L, et al. Blood. 2023 Apr 13;141(15):1817-1830. doi: 10.1182/blood.2022018246. Blood. 2023. PMID: 36706355 Free PMC article.
Recently, the ETCTN/CTEP 10026 study tested the combination of the DNA methyltransferase inhibitor decitabine together with the immune checkpoint inhibitor ipilimumab for AML/myelodysplastic syndrome (MDS) either after allogeneic hematopoietic stem cell transplantation (HS …
Recently, the ETCTN/CTEP 10026 study tested the combination of the DNA methyltransferase inhibitor decitabine together with the immun …
5,260 results